Drug Metabolism Considerations

Drug metabolism, predominantly mediated by hepatic cytochrome P450 enzymes, determines both a compound's systemic half-life and its potential for clinically...

Drug metabolism, predominantly mediated by hepatic cytochrome P450 enzymes, determines both a compound's systemic half-life and its potential for clinically significant drug–drug interaction, and is therefore a central and recurring consideration throughout lead optimization. Structural features associated with rapid oxidative metabolism — electron-rich aromatic rings, benzylic positions, and certain heteroatom-adjacent carbons — are identified through in-vitro metabolic stability screening using human or animal liver microsomes, and are systematically addressed through the ring modification, bioisosteric replacement, and strategic fluorination approaches introduced above, each capable of blocking a specific metabolically labile site while preserving the compound's essential pharmacophoric interactions.